Elutia vs Lineage Cell Therapeutics
ELUT and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELUT and LCTX compare
Lineage Cell Therapeutics is the larger company, worth 6.4 times as much as Elutia ($231M against $36.3M).
Elutia grew revenue faster over the last twelve months (79.4% versus 0.18% for Lineage Cell Therapeutics).
Elutia keeps more of each dollar of sales as profit, with a net margin of 321% compared with 16.2% at Lineage Cell Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELUT | LCTX |
|---|---|---|
| Size and price | ||
| Market cap | $36.3M | $231M |
| Share price | $0.820 | $0.915 |
| Change, 1 year | 10.8% | −52.6% |
| Change, 5 years | −85.9% | −60.1% |
| Beta (5Y) | 0.25 | 0.96 |
| Employees | 26 | 77 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× (better) | 21.3× |
| P/B | 2.4× (better) | 3.4× |
| FCF yield | −140% | −11.4% (better) |
| Fair value | $1.05 | $0.620 |
| Margin of safety | 21.9% (better) | −47.6% |
| Growth | ||
| Revenue growth (TTM) | 79.4% (better) | 0.18% |
| Revenue growth, 5Y average | −22.0% | 51.5% (better) |
| Profitability | ||
| Gross margin | 57.7% | – |
| Operating margin | −152% (better) | −280% |
| Net margin | 321% (better) | 16.2% |
| FCF margin | −299% | −244% (better) |
| Return on equity | – | 3.9% |
| Return on invested capital | – | −1395% |
| Financial health | ||
| Debt / equity | 0.53 (better) | 0.00 |
| Current ratio | 2.63 | 5.96 (better) |
| Altman Z-score | −5.70 | −2.87 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.8% | 46.1% |
| Held by insiders | 52.0% | 74.4% |
| Insider net buying, 12 months | $212K (better) | $24.4K |
| Short interest, % of float | 0.16% | 37.7% |
Go deeper
- ELUT stock overview
- ELUT income statement
- ELUT valuation and score
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.